Connect with us

Press Release US

Cannabis Products Global Market Report 2023



New York, Feb. 08, 2023 (GLOBE NEWSWIRE) — announces the release of the report “Cannabis Products Global Market Report 2023” –

The global cannabis products market is expected to grow from $28.0 billion in 2021 to $35.0 billion in 2022 at a compound annual growth rate (CAGR) of 25.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The cannabis products market is expected to reach $80.0 billion in 2026 at a CAGR of 23.0%.

The cannabis products market consists of sales of cannabis vape products, cannabis edibles, cannabis topicals, and cannabis oral products.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The value of goods in this market includes related services sold by the creators of the goods.

Cannabis products refer to a cannabis that has undergone a process that turns the plant material into a concentrate, such as, but not limited to, concentrated cannabis, or an edible or topical product containing cannabis or concentrated cannabis and other substances. It is frequently used as a recreational drugs and has several medical applications, including the treatment of migraines, nausea, and vomiting.

North America was the largest region in the cannabis products market in 2022.Middle East is expected to be the fargest growing region in the forecast period.

The regions covered in the cannabis products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of products are flowers, concentrates, and others.The smokable section of the cannabis plant, also known as the bud or nug, is referred to as the flower, bud, or nug.

The different compounds include THC-dominant, CBD-dominant, balanced THC & CBD and can be used in medical, and recreational. The various routes of administration include oral solutions and capsules, smoking, vaporizers, topicals, and others.

The growing applications of cannabis in the medical field are an important driver for the cannabis products market.Cannabis is a drug that comes from Indian hemp plants such as Cannabis sativa and Cannabis indica, with THC (delta-9 tetrahydrocannabinol) being the main active chemical in it.

Cannabis has several medical applications in conditions such as nausea and vomiting, glaucoma, epilepsy, and asthma.Hence, many countries have legalized the use of cannabis for medical applications despite it being a psychoactive drug.

Medical applications of cannabis include treating cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, AIDS, Alzheimer’s disease, and Parkinson’s disease. According to Harvard Health, around 85% of Americans supported legalizing medical marijuana, and at least several million Americans were using it.

The presence of several legal norms related to the use and possession of cannabis is an important restraint on the cannabis products market.These norms include regulations of the Food and Drug Administration (FDA) as well as rules set up by the government of each state in the USA.

The FDA reviews all applications of cannabis products for their safety and effectiveness.Despite having laws allowing cannabis businesses, many states in the USA still do not allow such businesses.

For instance, Los Angeles, San Francisco, San Jose, and San Diego have laws allowing cannabis businesses, but 80% of California’s nearly 500 municipalities do not allow retail marijuana businesses.

Solar cannabis cultivation is an emerging trend in the cannabis products market.As cannabis cultivation requires a large amount of energy for lighting, heating, air-conditioning, and dehumidification systems, cannabis product manufacturing companies are investing in solar cannabis cultivation.

This is mainly a result of legalizing cannabis products in various states of the USA, which is continuously increasing the consumption of energy and leading cannabis manufacturers to opt for solar cannabis cultivation. For instance, Aurora acquired 71 acres of land in Medicine Hat, Alberta, and installed a high-technology hybrid greenhouse cannabis production facility.

The government of California regulates the safety of manufacturing cannabis under the California Code of Regulations, Title 17 Division 1.It states that every manufacturer of cannabis products should obtain a valid license issued by a state cannabis licensing agency.

To obtain an annual license for cannabis manufacturing, the manufacturer should submit the physical address of the manufacturing premises and a written security plan.The security plan should include security measures to prevent access of unauthorized people into the manufacturing premises and prevention of loss or theft of cannabis and cannabis products.

Hence, this is expected to maintain a vigil on the manufacturing of cannabis in the coming years.

In May 2020, Aurora Cannabis Inc., a Canada-based cannabinoids company acquired Reliva, LLC for an undisclosed amount. Through this acquisition, Aurora and Reliva will be able to build a market-leading international cannabinoid platform, and they will be able to offer stable revenue and enhanced profitability. Reliva, LLC is a US-based company and a pacesetter in delivering high-quality hemp-derived CBD products to consumers.

The countries covered in the cannabis products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The cannabis products market research report is one of a series of new reports that provides cannabis products market statistics, including cannabis products industry global market size, regional shares, competitors with a cannabis products market share, detailed cannabis products market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis products industry. This cannabis products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

Source link

Continue Reading

Press Release US

Pampa Hemp Introduces First Medical Cannabis Seed Developed and Produced in Argentina




Argentina has been developing its cannabis production chain in recent years, promoting medical and scientific research on the medicinal use of the plant and its derivatives, as well as its industrial use. Pampa Hemp has recently been able to develop and produce the first medical cannabis seed in Argentina. The news will benefit the whole cannabis industry in the country.

Pampa Hemp, an Argentinean SME dedicated to the research, development, and production of cannabis for medicinal purposes, announces a historic achievement in the country with the approval of its first native cannabis seed variety, PH LOBERA, by the National Seed Institute (INASE).

Read more about Pampa Hemp and find the latest cannabis news with the mobile app.

This scientific breakthrough achieved by Pampa Hemp is important for the entire cannabis industry, as it eliminates the need to import seeds

After more than several years of research and development work, this new seed variety has been approved and is now part of Argentina’s National Cultivar Registry. Authorized local producers and people registered in the Reprocann (National Registry of Patients in Treatment with Cannabis) can now acquire the seed and obtain better results thanks to its ability to better adapt to the climatic conditions of the region. In addition, this scientific breakthrough is important for the entire cannabis industry, as it eliminates the need to import seeds.

“Our goal was to create a variety that has excellent adaptation to the soil, climate, and resistance to the pests that exist in the Province of Buenos Aires for outdoor cannabis crops. It also has a high concentration of THC and CBG, the latter a cannabinoid that is not so easy to find and is being increasingly observed for the therapeutic benefits it offers as an anti-inflammatory and pain reliever. We are currently working on genotyping tasks and molecular markers that will allow us to continue with the photo-improvement work,” explained Sebastian Tedesco, Technical Director and Co-Founder of Pampa Hemp.

This development began as an idea in 2017, with different tests being carried out by Pampa Hemp in a field in Lobos with various seed varieties to find the one that would best adapt to the soil and coexist better with native plant species. This process was the kick that led to the creation of a new strain that is now available on the market.

The registration of PH LOBERA in the registry is one more step towards the consolidation of the cannabis sector in Argentina, which seeks to promote medical and scientific research, as well as the industrial development of the crop. The official recognition of this strain will contribute to the growth of the cannabis production chain and to the strengthening of Argentina’s position in the global market of hemp and cannabis products.

Source link

Continue Reading

Press Release US

Heritage Cannabis Receives First Purchase Order and Is Set to Begin Shipments of CBD Products to Brazil




TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that it has received a purchase order from a Brazilian pharmaceutical CBD product importation and distribution company, to supply finished CBD products for wholesale distribution that have already received approval for sale in Brazil. These products are among the first products of their kind to be approved by the Brazil Health Authority (ANVISA) and will ship upon approval by Health Canada.

“This is just a starting point for Heritage in Brazil as we are in the process of establishing a long-term supply agreement for CBD products which will also include access to our entire THC product portfolio once medical use cannabis becomes fully legalized in Brazil.”

Tweet this

In 2021, Health Canada granted Heritage with a license to export cannabis products from Canada to Brazil. This will mark the first full shipment of products following the prior successful shipment to Brazil made by Heritage for the testing phase with ANVISA.

“We are very pleased to be in a position to expand our products and brands on a global scale, and to be working with a well recognized partner and their large distribution network in Brazil,” said David Schwede, CEO of Heritage. “This is just a starting point for Heritage in Brazil as we are in the process of establishing a long-term supply agreement for CBD products which will also include access to our entire THC product portfolio once medical use cannabis becomes fully legalized in Brazil.”

About Heritage Cannabis Holdings Corp.

Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, Thrifty, feelgood., the CB4 suite of medical products in Canada and ArthroCBD in the U.S.


“David Schwede”
David Schwede, CEO

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

Source link

Continue Reading

Press Release US

CannaPharmaRx Signs Supply Agreement with Y.S.A Holdings for up to $15 Million Annually of Commercial Cannabis




CALGARY, AB / ACCESSWIRE / March 30, 2023 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has signed a Supply Agreement with Israeli company Y.S.A Holdings (“YSA”). The business arrangement sets forth a supply agreement between the two companies.

Under the terms of the agreement, CannaPharmaRx will cultivate commercial cannabis at its Facility in Canada and supply YSA Group material for the sole purpose of selling finished product in Israel and Morocco. The agreement shall initially be for 24 months and automatically renews for periods of 24 months each.

YSA will buy from CannaPharmaRX a minimum of 400kg of Material per annum per each country comprising the Territory during the Term. It is anticipated that purchase orders will be between 400kg and 1000kg and occur as often as four times annually. Deliveries are anticipated to begin in Q3 quarter. Anticipated Revenues can be between $6 – $15 million on a yearly basis depending on quantity and timing.

“In accordance with the company’s model, we are building an international brand for our product. For this agreement, the brand will contain up to fifteen strains from the large pool of CannapharmaRX’s exclusive inventory. This is an important agreement for us as YSA’s CEO has significant experience in this industry and specifically in the international marketplace. Until recently he was the CEO of Teva Adir, one of the original and leading cannabis companies in Israel and currently advises the Moroccan government on the regulation issues required to market cannabis in the field. We continue to grow our customers and distribution across the globe,” stated Nick Colvin, CEO of CannaPharmaRx.

About CannapharmaRx, Inc.

CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx’s business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

Safe Harbor Statement

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are ‘forward-looking information or statements.’ Forward-looking information or statements can be identified by the use of words such as ‘plans,’ ‘expects,’ or ‘does not expect,’ ‘is expected,’ ‘estimates,’ ‘intends,’ ‘anticipates,’ or ‘does not anticipate,’ or ‘believes,’ or variations of such words and phrases or statements that certain actions, events or results ‘may,’ ‘could,’ ‘would,’ ‘might’ or ‘will’ be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media